301 Hospital

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

ZAP Surgical Receives National Medical Products Administration (NMPA) Approval in China

Retrieved on: 
Thursday, June 29, 2023
Robotics, Medical Supplies, Health, Technology, Surgery, Radiology, Stanford University, Multimedia, ZAP, Patient safety, 301 Hospital, National Medical Products Administration, PLA, Isotope, NMPA, Pharmaceutical industry, Medical imaging, Neurosurgery

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that the company received National Medical Products Administration (NMPA) approval in China for its ZAP-X® Gyroscopic Radiosurgery® platform.

Key Points: 
  • ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that the company received National Medical Products Administration (NMPA) approval in China for its ZAP-X® Gyroscopic Radiosurgery® platform.
  • (Photo: Business Wire)
    ZAP-X was previously granted NMPA’s Chinese Medical Device Evaluation (CMDE) Green Pathway, an accelerated path for the examination and approval of innovative medical devices.
  • PLAGH 301 is the largest hospital in China with more than 20,000 outpatient treatments per day.
  • “Following an intensive, multi-year effort we’re incredibly excited that the ZAP-X has finally received its regulatory approval in China,” said Dr. John R. Adler, Stanford Professor of Neurosurgery and Founder & Chief Executive Officer of ZAP Surgical Systems.

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

Retrieved on: 
Friday, March 17, 2023
Survival rate, IIT, Center for Drug Evaluation and Research, DC, Clinical trial, Cancer, Chinese, B cell, Messenger, Patient, National Medical Products Administration, Immune system, 301 Hospital, CDE, Hospital, Recurrence, IND, NMPA, Tumor-associated calcium signal transducer, Safety, Pharmaceutical industry, Vaccine

This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.

Key Points: 
  • This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
  • LK101 Injection, the first in-house developed cancer vaccine candidates by Likang, is a personalized neoantigen-targeted cancer vaccine and also a dendritic cell (DC)-based mRNA vaccine that combines advantages of both mRNA technology and DC by transducing mRNA encoding personalized tumor antigen targets based on dozens of patient-specific tumor mutations information into dendritic cells.
  • The combination of mRNA vaccine and DC vaccine provides a potential breakthrough in the field of personalized neoantigen treatment, offering an effective and safe approach for patients to fight against cancer.
  • In 2018, Likang collaborated with the Chinese PLA General Hospital to conduct an investigator-initiated clinical trial (IIT) of LK101 injection for postoperative liver cancer patients.

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

Retrieved on: 
Friday, March 17, 2023
Survival rate, IIT, Center for Drug Evaluation and Research, DC, Clinical trial, Cancer, Chinese, B cell, Messenger, Patient, National Medical Products Administration, Immune system, 301 Hospital, CDE, Hospital, Recurrence, IND, NMPA, Tumor-associated calcium signal transducer, Safety, Pharmaceutical industry, Vaccine

This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.

Key Points: 
  • This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
  • LK101 Injection, the first in-house developed cancer vaccine candidates by Likang, is a personalized neoantigen-targeted cancer vaccine and also a dendritic cell (DC)-based mRNA vaccine that combines advantages of both mRNA technology and DC by transducing mRNA encoding personalized tumor antigen targets based on dozens of patient-specific tumor mutations information into dendritic cells.
  • The combination of mRNA vaccine and DC vaccine provides a potential breakthrough in the field of personalized neoantigen treatment, offering an effective and safe approach for patients to fight against cancer.
  • In 2018, Likang collaborated with the Chinese PLA General Hospital to conduct an investigator-initiated clinical trial (IIT) of LK101 injection for postoperative liver cancer patients.

CGTN: China sees off Comrade Jiang Zemin, pooling strength for striving forward

Retrieved on: 
Wednesday, December 7, 2022
Memory, Flood, Great hall, 301 Hospital, Woman, Conference, Environment, Life, Orientation, Shanghai Jiao Tong University, Flower, Letter, Chinese Communist Party, 2009 Davis Cup, HKSAR, Liaison Office, World Trade Organization, Rejuvenation, Great Hall of the People, CPC, Central committee, Face, Eulogy, News, Communist party, Babaoshan, UN, World Conference on Women, 1995, Hospital, Socialism, Hong Kong Liaison Office, Babaoshan Revolutionary Cemetery, SARS, Hearing, Comrade, Grief, Shipbuilding, Drug, Risk management, Chinese, Party, Xi

People across the country paid a three-minute silent tribute on Tuesday morning when a mourning session was held at a solemn memorial meeting.

Key Points: 
  • People across the country paid a three-minute silent tribute on Tuesday morning when a mourning session was held at a solemn memorial meeting.
  • Jiang guaranteed the great ship of China's reform, opening-up, and socialist modernization forges ahead on the right track, Xi said.
  • Eric Chu, chairman of the Chinese Kuomintang party, as well as Taiwan compatriots on the mainland, also expressed their condolences over the passing of Jiang.
  • He also called the reform and opening-up a crucial move in determining the future and destiny of contemporary China.

CGTN: China sees off Comrade Jiang Zemin, pooling strength for striving forward

Retrieved on: 
Wednesday, December 7, 2022
Memory, Flood, Great hall, 301 Hospital, Woman, Conference, Environment, Life, Orientation, Shanghai Jiao Tong University, Flower, Letter, Chinese Communist Party, 2009 Davis Cup, HKSAR, Liaison Office, World Trade Organization, Rejuvenation, Great Hall of the People, CPC, Central committee, Face, Eulogy, News, Communist party, Babaoshan, UN, World Conference on Women, 1995, Hospital, Socialism, Hong Kong Liaison Office, Babaoshan Revolutionary Cemetery, SARS, Hearing, Comrade, Grief, Shipbuilding, Drug, Risk management, Chinese, Party, Xi

People across the country paid a three-minute silent tribute on Tuesday morning when a mourning session was held at a solemn memorial meeting.

Key Points: 
  • People across the country paid a three-minute silent tribute on Tuesday morning when a mourning session was held at a solemn memorial meeting.
  • Jiang guaranteed the great ship of China's reform, opening-up, and socialist modernization forges ahead on the right track, Xi said.
  • Eric Chu, chairman of the Chinese Kuomintang party, as well as Taiwan compatriots on the mainland, also expressed their condolences over the passing of Jiang.
  • He also called the reform and opening-up a crucial move in determining the future and destiny of contemporary China.

Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment

Retrieved on: 
Friday, September 17, 2021
People, WebRTC, Degenerative disease, Wu Zhongchao, Efficiency, Technology, Hematology, Forward-looking statement, MDT, Coronavirus, First Affiliated Hospital of Xinjiang Medical University, Patient, Company, Private Securities Litigation Reform Act, Microbiology, Second Affiliated Hospital of Xinjiang Medical University, Disease, Human, Physician, Infection, Medicine in China, Hospital, NASDAQ, Solution, Growth, Chinese Medical Doctor Association, Neoplasm, Review, Learning, Lists of diseases, Guangzhou Medical University, Diagnosis, Goal, SEC, Cancer, 301 Hospital, Chongqing Medical University, Ruijin Hospital, Medicine, Public relations

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), aninternet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform").

Key Points: 
  • SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), aninternet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform").
  • The Hematology MDT Platform provides clinicians with a channel to learn multidisciplinary thinking skills online, in order to improve diagnosis and treatment and further the efficiency of treatment.
  • In addition, physicians can watch MDT training videos to learn the clinical thinking skills from experts and improve their problem-solving ability during the disease diagnosis and treatment.
  • Zhongchao's Hematology MDT platform provides physicians with a convenient and rapid access to learn and exchange MDT practices and experiences andwill promote the development of hematology treatment models in China.